BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Study Promising Candidate in Phase 2 GBM Trial

May 26, 2021 12:27:13

CNS Pharmaceuticals (NASDAQ: CNSP) is on track to begin a potentially pivotal Phase 2 trial during the second quarter of 2021. This trial of CNSP’s lead drug candidate, Berubicin, in the treatment of glioblastoma multiforme (“GBM”) is currently planned to include up to 243 subjects, randomized 2:1 (162 Berubicin/81 Lomustine) with an interim analysis when 50% of the subjects reach six months in the study. “As the first anthracycline to cross the blood-brain barrier, Berubicin was specifically designed to attack a variety of primary brain cancers and cancers metastatic to the brain,” reads a recent article on the novel candidate. “Dr. Waldemar Priebe, professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center, is the original developer of Berubicin. The Phase 1 trial was completed by Reata Pharmaceuticals (NASDAQ: RETA) and showed promising results, with 44% of the trial patients experiencing significant improvement in clinical benefit. One patient from this trial has survived cancer-free for the last 14 years, while two others saw a reduction in tumor size of up to 80%.”

To view the full article, visit https://ibn.fm/kH8lJ

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme, an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork